| Lourdes Uy, MD | |
|
100 Hospital Rd, Leominster, MA 01453-2253 | |
| (978) 466-4550 | |
| (978) 466-4561 |
| Full Name | Lourdes Uy |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 35 Years |
| Location | 100 Hospital Rd, Leominster, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831419829 | NPI | - | NPPES |
| 110098653A | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 264665 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Umass Memorial Medical Center/university Campus | Worcester, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Umass Memorial Medical Group Inc | 4284539891 | 1889 |
News Archive
Designing nanomedicine to combat diseases is a hot area of scientific research, primarily for treating cancer, but very little is known in the context of atherosclerotic disease.
Delays in the launch and execution of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs. It is, therefore, absolutely critical for biopharmaceutical companies to develop a tactical approach to expedite the market research approval process for quicker and more meaningful insights.
Liver toxicity is one of the main reasons pharmaceutical companies pull drugs off the market. These dangerous drugs slip through approval processes due in part to the shortcomings of liver toxicity tests. Existing tests rely on liver cells from rats, which do not always respond to toxins the way human cells do. Or they rely on dying human cells that survive for only a few days in the lab.
A new study in the Journal of Neurophysiology by researchers at the University of Kansas Life Span Institute is the first to look at functional brain activity in people with autism spectrum disorder (ASD) while they performed precision visuomotor behavior - in this case, a grip-force test.
Vermont is moving one step closer to a goal of its Democratic governor: a state-run health plan that would insure most of its 625,000 residents. The bill Gov. Peter Shumlin plans to sign on Thursday would create a panel whose goal would be to figure out how to pay for a new system intended to reduce the rate of overall health-cost increases.
› Verified 9 days ago
| Entity Name | Umass Memorial Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760445373 PECOS PAC ID: 4284539891 Enrollment ID: O20040113000267 |
News Archive
Designing nanomedicine to combat diseases is a hot area of scientific research, primarily for treating cancer, but very little is known in the context of atherosclerotic disease.
Delays in the launch and execution of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs. It is, therefore, absolutely critical for biopharmaceutical companies to develop a tactical approach to expedite the market research approval process for quicker and more meaningful insights.
Liver toxicity is one of the main reasons pharmaceutical companies pull drugs off the market. These dangerous drugs slip through approval processes due in part to the shortcomings of liver toxicity tests. Existing tests rely on liver cells from rats, which do not always respond to toxins the way human cells do. Or they rely on dying human cells that survive for only a few days in the lab.
A new study in the Journal of Neurophysiology by researchers at the University of Kansas Life Span Institute is the first to look at functional brain activity in people with autism spectrum disorder (ASD) while they performed precision visuomotor behavior - in this case, a grip-force test.
Vermont is moving one step closer to a goal of its Democratic governor: a state-run health plan that would insure most of its 625,000 residents. The bill Gov. Peter Shumlin plans to sign on Thursday would create a panel whose goal would be to figure out how to pay for a new system intended to reduce the rate of overall health-cost increases.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lourdes Uy, MD Po Box 415348, Boston, MA 02241-5348 Ph: () - | Lourdes Uy, MD 100 Hospital Rd, Leominster, MA 01453-2253 Ph: (978) 466-4550 |
News Archive
Designing nanomedicine to combat diseases is a hot area of scientific research, primarily for treating cancer, but very little is known in the context of atherosclerotic disease.
Delays in the launch and execution of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs. It is, therefore, absolutely critical for biopharmaceutical companies to develop a tactical approach to expedite the market research approval process for quicker and more meaningful insights.
Liver toxicity is one of the main reasons pharmaceutical companies pull drugs off the market. These dangerous drugs slip through approval processes due in part to the shortcomings of liver toxicity tests. Existing tests rely on liver cells from rats, which do not always respond to toxins the way human cells do. Or they rely on dying human cells that survive for only a few days in the lab.
A new study in the Journal of Neurophysiology by researchers at the University of Kansas Life Span Institute is the first to look at functional brain activity in people with autism spectrum disorder (ASD) while they performed precision visuomotor behavior - in this case, a grip-force test.
Vermont is moving one step closer to a goal of its Democratic governor: a state-run health plan that would insure most of its 625,000 residents. The bill Gov. Peter Shumlin plans to sign on Thursday would create a panel whose goal would be to figure out how to pay for a new system intended to reduce the rate of overall health-cost increases.
› Verified 9 days ago
Germaine Earle-cruickshanks, D.O Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 60 Hospital Rd, Health Alliance Hospital, Leominster, MA 01453 Phone: 978-466-2000 | |
Diane T. Power, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 50 Memorial Dr, Suite 205, Leominster, MA 01453 Phone: 978-466-4550 | |
Laura K. Silk, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 100 Hospital Rd, Suite 1b, Leominster, MA 01453 Phone: 978-466-4550 | |
Elizabeth R Darr, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 165 Mill St, Leominster, MA 01453 Phone: 978-466-3207 Fax: 978-534-3581 | |
Leyla Sahin, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 100 Hospital Rd, Suite 1 B, Leominster, MA 01453 Phone: 978-466-4550 Fax: 978-466-4507 | |
Dr. Robert Edward Dalessandro, Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 23 Theresa Ave, Leominster, MA 01453 Phone: 978-534-5212 | |
Sridhar S. Iyer, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 100 Hospital Rd, Suite 1b, Leominster, MA 01453 Phone: 978-466-4550 |